Evidence map›Paper›PMID 33005990›Full record

ArticleInternational orthopaedics2021

Evaluation of biomarkers of joint damage in patients subjected to arthroscopy.

Aldo Izaguirre, Guadalupe González-Gutiérrez, Sixto Elmer Galindo-López, Gustavo Arenas-Serna, Amado Rodríguez, Enrique Flores-Torrero, Rebecca Elizabeth Franco Y Bourland, Martha Alicia Ballinas-Verdugo, Fausto Sánchez-Muñoz

Abstract read
PubMed Publisher
In one paragraph

Article in International orthopaedics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Aldo IzaguirreUniversidad Autónoma de Tamaulipas / Hospital Naval de Tampico, Investigación , Circuito Universitario, 89109, Tampico, Mexico. aldoizag@gmail.com.ORCID http://orcid.org/0000-0001-5769-9359
Guadalupe González-GutiérrezCentro de Rehabilitación Integral Teletón, Altamira, Tamaulipas, Mexico.
Sixto Elmer Galindo-LópezHospital Naval de Tampico, Tampico, Mexico.
Gustavo Arenas-SernaHospital Médica Universidad, Tampico, Mexico.
Amado RodríguezHospital Regional Cd. Madero PEMEX, Ciudad Madero, Mexico.
Enrique Flores-TorreroSports Clinic Tampico, Tampico, Mexico.
Rebecca Elizabeth Franco Y BourlandInstituto Nacional de Rehabilitación, Mexico City, Mexico.
Martha Alicia Ballinas-VerdugoNational Institute of Cardiology, Mexico City, Mexico.
Fausto Sánchez-MuñozNational Institute of Cardiology, Mexico City, Mexico.
Universidad del Noreste · MXInstituto Nacional de Cardiología · MXAutonomous University of Tamaulipas · MXInstituto Nacional de Rehabilitación · MXInstituto Tecnológico de Ciudad Madero · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRecently, the determination of biochemical markers has been intensely explored to better understand the mechanisms underlying knee OA. In this study, we aimed to explore the expression pattern of five biochemical markers in patients with knee OA.

methodsAfter IRB approval and signed informed consent, 26 patients were enrolled. Serum and synovial samples were collected prior to knee arthroscopy. Pre-operative assessment included diagnosis, Lysholm, Tegner Activity Scale, IKDC score, and radiographic Kellgren and Lawrence classification. ELISA of CTX-I, CTX-II, NTX-I, MMP3, and MMP13 were measured in serum and synovial fluid samples.

resultsTwenty-six patients were included, with a mean age of 42 ± 15 years old. Mean results and standard deviation of the biomarkers in serum were as follows: CTX-I 5.8 ± 5.5 ng/mL, CTX-II 3.8 ± 1.7 ng/mL, NTX-I 52 ± 71 (nM BCE), MMP3 1.18 ± 0.6 ng/mL, and MMP13 1243.6 ± 1422 pg/mL; synovial fluid results were as follows: CTX-I 0.74 ± 0.5 ng/mL, CTX-II 5.1 ± 2.5 ng/mL, NTX-I 254 ± 85 (nM BCE), MMP3 0.4 ± 0.4 ng/mL, and MMP13 797 ± 1391 pg/mL. We observed a differential pattern of expression in serum NTX-I in patients with chronic meniscus injuries when compared with ACL injuries or cartilage lesions.

conclusionsIn conclusion, the clinical criteria of early OA are useful to categorize patients with knee conditions. The biochemical markers explored did not yield a differential pattern that can be associated with this classification. Serum NTX-I could be a useful marker of chronic meniscal lesion in future longitudinal studies, after adjusting for age and sex.

Indexed as

ArthroscopyOsteoarthritis, KneeAdultBiomarkersHumansKnee JointMiddle AgedSynovial FluidBiomarkersBiomarkersClinical criteriaKnee osteoarthritis

Identifiers

PMID33005990
OpenAlexW3089475318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.